Ferrata Storti Foundation

SHERPA: Unknown

People

  1. Tallman
    Tallman
  2. Levine
    Levine
  3. Zelenetz
    Zelenetz
  4. Mauro
    Mauro
  5. Stein
    Stein
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Salles
    Salles
  9. Horwitz
    Horwitz
  10. Perales
    Perales

Groups

  1. Department of Medicine (296)
  2. Hematologic Malignancies, Division of (295)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)
  7. Executive Committee, Center for Hematologic Malignancies (60)
  8. Hematologic Malignancies Research (45)
  9. Sloan Kettering Institute Postdocs (44)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (41)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (124)
  3. Research Letter (26)
  4. Editorial (17)
  5. Review (12)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (296)
  2. Hematologic Malignancies, Division of (295)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)

More Groups

People
  1. Carl Landgren (25)
  2. Martin Tallman (25)
  3. Andrew Zelenetz (24)
  4. Ross Levine (24)
  5. Michael Mauro (21)
  6. Anas Younes (16)

More People

Years
  1. 2025 (19)
  2. 2024 (23)
  3. 2023 (17)
  4. 2022 (20)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Haematologica (355)
  2. Haematologica Meeting Reports (4)

Results (359)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Davids, M. S.; Roberts, A. W.; Seymour, J. F.; Wierda, W. G.; Puvvada, S. D.; Gressick, L.; Alter, D.; Zhou, L.; Kim, S. Y.; Verdugo, M.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Phase 3 ALCANZA study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (Bex) in CD30-positive cutaneous T-cell lymphoma (CTCL): Number needed to treat analysis
    Meeting Abstract

    Zagadailov, E.; Prince, H. M.; Whittaker, S.; Horwitz, S.; Duvic, M.; Kim, Y.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Timing of defibrotide initiation post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after primary chemotherapy: Exploratory analysis of an expanded-access protocol
    Meeting Abstract

    Kernan, N.; Richardson, P.; Triplett, B.; Grupp, S.; Antin, J.; Liang, W.; Hume, R.; Tappe, W.; Soiffer, R.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Multiple myeloma and comorbidity: A population-based study
    Meeting Abstract

    Sverrisdottir, I. S.; Rögnvaldsson, S.; Lund, S. H.; Turesson, I.; Hultcrantz, M.; Björkholm, M.; Landgren, O.; Kristinsson, S. Y.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Defibrotide efficacy and safety in patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) diagnosed after day 21: Analysis of final data from an expanded-access program
    Meeting Abstract

    Richardson, P.; Smith, A.; Triplett, B.; Kernan, N.; Grupp, S.; Antin, J.; Lehmann, L.; Giralt, S.; Ryan, R.; Hume, R.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of defibrotide in the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following hematopoietic stem cell transplantation: Final subgroup results
    Meeting Abstract

    Richardson, P.; Smith, A.; Triplett, B.; Kernan, N.; Grupp, S.; Antin, J.; Lehmann, L.; Giralt, S.; Liang, W.; Hume, R.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Prognostic tools can provide personalized outcomes prediction after allogeneic HCT in patients with hematologic malignancies
    Meeting Abstract

    Cho, C.; Devlin, S.; Hilden, P.; Maloy, M.; Horowitz, M.; Rizzo, J. D.; Logan, B.; Barba, P.; O'Reilly, R.; Giralt, S.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Differentiation syndrome associated with enasidenib (AG-221), a selective inhibitor of mutant isocitrate dehydro-genase 2 (mIDH2)
    Meeting Abstract

    Fathi, A. T.; DiNardo, C. D.; Kline, I.; Kenvin, L.; Gupta, I.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Haematologica (2017)

    Fulltext@MSK | Save
  • AICDA drives epigenetic heterogeneity in germinal center-derived lymphomas and accelerates lymphomagenesis
    Meeting Abstract

    Dominguez, P. M.; Teater, M.; Redmond, D.; Chen, Z.; Ennishi, D.; Scott, D. W.; Cimmino, L.; Ghione, P.; Chaudhuri, J.; Gascoyne, R. D.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Improved survival in 21,465 multiple myeloma patients: Results from a population-based study
    Meeting Abstract

    Thorsteinsdottir, S.; Dickman, P. W.; Turesson, I.; Landgren, O.; Hultcrantz, M.; Björkholm, M.; Kristinsson, S. Y.
    Haematologica (2017)

    Fulltext@MSK | Save

    • Ferrata Storti Foundation – authorized name for: